Pharma finds a way to gain weight
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
EHA 2023 – Astrazeneca keeps up its complement defence
With Novartis’s oral contender looming, Astra talks up the importance of terminal complement inhibition.
Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.
2023’s biggest launches: the story so far
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
Astellas doesn’t buy Apellis
In purchasing Iveric for $5.9bn the Japanese group has plumped for the cheaper geographic atrophy player.
Biopharma stocks go back to bleak
Hopes for a better 2023 look optimistic as markets take another turn for the worse.